Completed
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
NCT00250614
- Conditions
- Behavior, Behavioral Symptoms, Depression, +3 more
- Locations
-
- Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States